02/03/2016 - 2:52pm
ZembraceSymTouch marks the first approval Dr. Reddy’s has received from the FDA for a brand-name product in its neurology portfolio. 
02/03/2016 - 1:40pm

The asthma treatment is a once-daily dose of two 1.25-microgram puffs. 

02/03/2016 - 1:04pm

Reuters is reporting that in 2016, there will likely be seven blockbuster drugs launched, each of which has potential to see more than $1 billion in annual sales. The ones that are poised to be the biggest are a chronic liver desease drug from Intercept Pharmaceuticals and Gilead’s fixed-dose treatment for H.I.V, which experts forecast could make $2.6 billion and $2 billion, respectively. (Reuters)

02/02/2016 - 4:34pm

CDC has received recent reports of severe respiratory illness among young- to middle-aged adults with H1N1pdm09 virus infection, some of whom required intensive care unit admission; fatalities have been reported. 

02/01/2016 - 3:37pm

The availability of the antidote to opioid overdoses through retail pharmacy is increasing. 

02/01/2016 - 11:22am
The Chicago Tribune is reporting that pharmacy benefit manager Express Scripts has opted to block reimbursements for Valeant Pharmaceuticals’ Glumetza once the generic is launched on Feb. 1. According to GoodRx, the drug currently costs about $1,500 for a 30-day supply. “Recent agreements Valeant has signed with retail pharmacies now potentially encourage the pharmacies to bypass the more affordable generic,” Express Scripts said. “To protect our clients and patients from wasteful, unnecessary drug spend, Express Scripts will exclude Glumetza.” (Chicago Tribune)
 
01/29/2016 - 3:55pm

The drug showed in clinical trials that it had a sustained antidepressant effect following a one-day rapid effect. 

01/29/2016 - 3:14pm

According to the New York Times, Valeant Pharmaceuticals has issued a statement following criticism from Hillary Clinton’s presidential campaign about it raising the cost of the drug D.H. E., noting that there was a generic version of the drug available and that it had less than 1% of the market share on D.H.E, which costs $14,000 for 10 vials, $11,000 more than it cost in June 2014. “Whenever the sales volume of a drug declines, manufacturers must consider pricing adjustments to keep production of the drug viable,” the company said.  (New York Times)

01/29/2016 - 2:44pm
The drug is delivered via the Xsail breath-powered delivery device, allowing intranasal dosing of the most commonly prescribed migraine treatment.